These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36430230)

  • 1. Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma.
    Langendonk M; Smit NAM; Plattel W; Diepstra A; Meerten TV; Visser L
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Treatment with the BRAF
    Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response.
    Zhang L; Ramesh P; Steinmetz M; Medema JP
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical cancer treatment.
    Abdul Rahman SF; Xiang Lian BS; Mohana-Kumaran N
    Future Oncol; 2020 Oct; 16(28):2235-2249. PubMed ID: 32715755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.
    Vandenberg CJ; Cory S
    Blood; 2013 Mar; 121(12):2285-8. PubMed ID: 23341542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma.
    Mukherjee N; Strosnider A; Vagher B; Lambert KA; Slaven S; Robinson WA; Amato CM; Couts KL; Bemis JGT; Turner JA; Norris DA; Shellman YG
    Cell Death Dis; 2018 Sep; 9(9):907. PubMed ID: 30185782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
    Renault TT; Elkholi R; Bharti A; Chipuk JE
    J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.
    Deng J; Carlson N; Takeyama K; Dal Cin P; Shipp M; Letai A
    Cancer Cell; 2007 Aug; 12(2):171-85. PubMed ID: 17692808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
    Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
    Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
    Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
    Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs.
    Natoli A; Lüpertz R; Merz C; Müller WW; Köhler R; Krammer PH; Li-Weber M
    Int J Cancer; 2013 Oct; 133(8):1945-54. PubMed ID: 23553437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge.
    Melo G; Silva CAB; Hague A; Parkinson EK; Rivero ERC
    Oral Oncol; 2022 Sep; 132():105979. PubMed ID: 35816876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
    Roberts AW; Seymour JF; Brown JR; Wierda WG; Kipps TJ; Khaw SL; Carney DA; He SZ; Huang DC; Xiong H; Cui Y; Busman TA; McKeegan EM; Krivoshik AP; Enschede SH; Humerickhouse R
    J Clin Oncol; 2012 Feb; 30(5):488-96. PubMed ID: 22184378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Ng SY; Davids MS
    Clin Adv Hematol Oncol; 2014 Apr; 12(4):224-9. PubMed ID: 25003352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.
    Ju W; Zhang M; Wilson KM; Petrus MN; Bamford RN; Zhang X; Guha R; Ferrer M; Thomas CJ; Waldmann TA
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1624-9. PubMed ID: 26811457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells.
    Yang M; Wang L; Ni M; Neuber B; Wang S; Gong W; Sauer T; Sellner L; Schubert ML; Hückelhoven-Krauss A; Hong J; Zhu L; Kleist C; Eckstein V; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Front Immunol; 2020; 11():608167. PubMed ID: 33362794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.